Isoray Announces Transformational Merger and Fourth Quarter and Full-Year Fiscal Year End 2022 Financial Results

RICHLAND, Wash., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it has entered into a definitive agreement to acquire Viewpoint Molecular Targeting, Inc. (Viewpoint) a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents.

Read more at globenewswire.com